Asarina Pharma AB (publ)
ASAP.ST
Stockholm Stock Exchange0.03
SEK
-0.01
- -
Asarina Pharma AB (publ)
ASAP.ST
(Stockholm Stock Exchange)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Asarina Pharma AB (publ) is a Swedish biotechnology company focused on the development of neurosteroid-based treatments for neurological and menstrual-related disorders. The company's main product was Sepranolone, an endogenous compound designed to inhibit the negative effects of allopregnanolone, a neurosteroid implicated in conditions such as Tourette syndrome, premenstrual dysphoric disorder (PMDD), and other stress and compulsivity-driven disorders. Asarina's product pipeline includes the development of a new family of GABA-A Modulating Steroid Antagonists (GAMSA) aimed at providing safer, efficacious treatments for neurological conditions that currently lack effective pharmaceutical options. The company has conducted several clinical studies, including a Phase IIa clinical study for Sepranolone in Tourette syndrome which showed promising results in symptom improvement and safety. In recent major developments, Asarina Pharma decided in 2024 to discontinue its efforts to find a development partner for Sepranolone after an extensive partnering process yielded no acquisition or collaboration offers. Subsequently, the company applied for delisting from the Nasdaq First North Growth Market, with trading ceasing in October 2024. Following the delisting, Asarina Pharma entered voluntary liquidation, with the process expected to be completed in 2025. In February 2025, Asarina sold all intellectual property rights to Sepranolone to the US-based neurology company Relmada Therapeutics for a deal valued at approximately 3 million euros. This transfer grants Relmada full global ownership of Sepranolone, which it plans to develop further as a potential first-line treatment for Tourette syndrome and related disorders based on positive Phase 2a clinical data previously generated by Asarina. Founded in 2006 and headquartered in Stockholm, Sweden, Asarina Pharma specialized in the research and development of pharmacological treatments targeting allopregnanolone-related disorders. The company operated primarily in Europe but had partnerships and rights transactions involving entities in the United States. Before liquidation, its business segments included biotechnology drug development focused on neurological and menstrual disorders through innovative neurosteroid modulation. Asarina Pharma's recent strategic shift to liquidation and asset sale marks an operational closure of its proprietary clinical-stage assets and exit from active product development. This corporate description reflects Asarina Pharma AB's core product focus on Sepranolone and related GAMSA compounds, its clinical-stage development activities, and its recent business transition following the sale of its key asset and entry into voluntary liquidation.